Dual Epitope Anti-BCMA CAR-T Cells

Only %1 left

Catalog #

78790

As low as $1,650 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

The Dual Epitope Anti-BCMA CAR-T Cells are generated via high-titer lentiviral transduction of human primary CD4⁺and CD8⁺ T cells with the SIN Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ) (#78783). These ready-to use CAR (chimeric antigen receptor)-T cells express an anti-BCMA CAR consisting of a ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (VHH1 and VHH2) linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1).

These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and in co-culture cytotoxicity assays.

Figure 1: Construct diagram showing components of the anti-BCMA CAR expressed in Dual Epitope Anti-BCMA CAR-T Cells.

●

Product Data Gallery

Expression of anti-BCMA CAR in Dual Epitope Anti-BCMA CAR-T Cells.

Luciferase-based cytotoxicity assay using Dual Epitope Anti-BMCA CAR-T Cells co-cultured with BCMA-Luciferase CHO cells as target cells.

Luciferase-based cytotoxicity assay using Dual Epitope Anti-BMCA CAR-T Cells co-cultured with Firefly Luciferase - RPMI 8226 Recombinant Cell Line as the target cells.

Product Info

Storage and Usage

Citations

Supplied As

Each vial contains ˃1 x 10⁶ cells in 1 ml of CryoStor® CS10 (Stemcell Technologies #100-1061)

Materials Required But Not Supplied

Name	Ordering Information
Human Interleukin-2 Recombinant	BPS Bioscience #90184
Human CD3/CD28/CD2 T Cell Activator	Stemcell Technologies #10970
BCMA, Fc-Fusion, Avi-Tag, PE-Labeled Recombinant	BPS Bioscience #100733
Untransduced T Cells (as Negative Control for CAR-T cells)	BPS Bioscience #78170
Firefly Luciferase CHO Cell Line	BPS Bioscience #79725
BCMA/Firefly Luciferase CHO Cell Line	BPS Bioscience #79724
Firefly Luciferase RPMI8226 Cell Line	BPS Bioscience #79834
Thaw Medium 3	BPS Bioscience #60186
Thaw Medium 10	BPS Bioscience #79704
ONE-Step™ Luciferase Assay System	BPS Bioscience #60690
Luminometer

Recommended Anti-BCMA CAR-T Cell Medium: TCellM™ (#78753) supplemented with 10 ng/ml Interleukin-2 (#90184).

Mycoplasma Testing

The cells have been screened to confirm the absence of Mycoplasma species.

Background

BCMA (B-cell maturation antigen), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF (tumor necrosis factor) receptor superfamily that recognizes BAFF (B-cell activating factor). BCMA is preferentially expressed in mature B lymphocytes and in Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. BCMA CAR-Ts are primary T cells engineered by lentiviral transduction to express a fully human-specific BCMA-CAR. CAR-T cells targeting BCMA have shown clinical anti-MM activity, and in 2022, the FDA granted authorization to use LCAR-B38M CAR-T Cell immunotherapy in MM. Active research into the development of BCMA targeting CARs for the treatment of several oncogenic disorders is ongoing, and represents a promising therapeutic avenue in cancer therapy.

References

Ghosh A., et al., 2017 Leuk Lymphoma. 6:1-12
Sanchez E., et al., 2018 Expert Rev Mol Diagn. 7:1-11.
Sohail A., et al., 2018 Immunotherapy. 10(4):265-282.
Sidaway P., et al., 2016 Nat Rev Clin Oncol. 13(9):530.

Storage/Stability

Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at [email protected] if the cells are not frozen in dry ice upon arrival.

Applications

Positive control in anti-BCMA CAR-T development.
Screen modulators of anti-BCMA CAR-T driven cytotoxicity.
Design and optimize co-culture cytotoxicity assays.

Shipping Temperature

-80°C

Notes

Biosafety
The Dual Epitope Anti-BCMA CAR-T Cells are produced with the third generation SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle.

Troubleshooting Guide
Visit Cell Line FAQs for more information.
For further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles.

Donors have been screened and determined negative for:

Hepatitis B (anti-HBc EIA, HBsAg EIA)
Hepatitis C (anti-HCV EIA)
Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)
Human T-Lymphotropic Virus (HTLV-I/II)
HIV-1/HCV/HBV
West Nile Virus
Trypanasoma cruzi

Note: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate Biological Safety Level 2 (BSL-2) precautions should be used.

Scientific Category

Cancer Therapy Target

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Dual Epitope Anti-BCMA CAR-T Cells

PRODUCTS

SERVICES

RESOURCES

COMPANY